Amgen has entered an agreement to acquire biotechnology company Micromet, for approximately $1.2 billion in cash. The company was founded in Germany with its R&D center in Munich and headquarters in Rockville, MD. The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase II development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin’s lymphoma (NHL), and could have applications in o...